Is Penumbra Regaining Ground in the Ischemic Stroke Market?

After the launch of Penumbra’s new product, the RED 72 catheter, we took a look at its impact and other historical trends in the ischemic stroke market.

  • Qsight’s healthcare facility purchasing dataset shows the immediate impact of recalls and new product launches in the ischemic stroke market.
  • After the recall of the Jet 7 Xtra Flex catheter, Penumbra remained an industry leader, despite losing some share. However, the recent launch of the RED 72 catheter quickly boosted Penumbra’s share in September 2021, as seen in the first graph.
  • From August to September 2021, Penumbra’s RED 72 and RED 68 catheters are the top contributors to growth in the market, taking significant share from Imperative’s Zoom aspiration catheter and replacing Penumbra’s legacy Jet 7 and ACE68 catheters.

The above is based on Qsight’s healthcare facilities purchasing dataset analyzing over $200M from the top players in the ischemic stroke market across a panel of over 450 distinct healthcare facilities and hospitals.

For more information about Qsight data, contact us here

Post created by: Kenny Dolgin, VP of Quantitative Research, Guidepoint Qsight & Shimul Sheth, Quantitative Analyst, Guidepoint Qsight

Leave a comment

Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.